Associations between health and productivity in cow-calf beef herds and persistent infection with bovine viral diarrhea virus, antibodies against bovine viral diarrhea virus, or antibodies against infectious bovine rhinotracheitis virus in calves

OBJECTIVE: To measure associations between health and productivity in cow-calf beef herds and persistent infection with bovine viral diarrhea virus (BVDV), antibodies against BVDV, or antibodies against infectious bovine rhinotracheitis (IBR) virus in calves. ANIMALS: 1,782 calves from 61 beef herds. PROCEDURES: Calf serum samples were analyzed at weaning for antibodies against type 1 and type 2 BVDV and IBR virus. Skin biopsy specimens from 5,704 weaned calves were tested immunohistochemically to identify persistently infected (PI) calves. Herd production records and individual calf treatment and weaning weight records were collected. RESULTS: There was no association between the proportion of calves with antibodies against BVDV or IBR virus and herd prevalence of abortion, stillbirth, calf death, or nonpregnancy. Calf death risk was higher in herds in which a PI calf was detected, and PI calves were more likely to be treated and typically weighed substantially less than herdmates at weaning. Calves with high antibody titers suggesting exposure to BVDV typically weighed less than calves that had no evidence of exposure. CONCLUSIONS AND CLINICAL RELEVANCE: BVDV infection, as indicated by the presence of PI calves and serologic evidence of infection in weaned calves, appeared to have the most substantial effect on productivity because of higher calf death risk and treatment risk and lower calf weaning weight.     

Evaluation of a new sandwich enzyme-linked immunosorbent assay for detection of bovine viral diarrhea virus in unprocessed fetal bovine serum.

A new sandwich enzyme-linked immunosorbent assay (S-ELISA) kit that uses raw (unprocessed) fetal bovine serum (FBS) as the testing sample was evaluated for upstream bovine viral diarrhea virus (BVDV) testing. Pooled FBS samples (n = 84) were tested using the S-ELISA. Thirty serum samples originating from persistently infected (PI) calves that had been confirmed by virus isolation (VI) as BVDV positive and another 30 samples previously confirmed by VI as BVDV negative were also evaluated. Of the 84 field samples, the S-ELISA detected 13 (15.5%) BVDV-positive specimens. When these 13 positive samples were tested by VI and immunofluorescent assay, 11 (84.6%) were positive and 2 (15.4%) were negative. The S-ELISA was positive for all 30 PI samples (100%) and negative for all 30 negative samples (100%). These data indicate that the new kit is a relatively reliable diagnostic tool and can be considered for upstream detection of BVDV-contaminated raw FBS pools.     

Serological and molecular diagnosis of bovine viral diarrhoea virus and evidence of other viral infections in dairy calves with respiratory disease in Venezuela

An investigation based on 2 studies was carried out to assess the involvement of bovine virus diarrhoea virus (BVDV), bovine herpesvirus type 1 (BHV-1), and bovine respiratory syncytial virus (BRSV) in calf respiratory disease in dairy farms in Venezuela. In the first study, 8 farms were selected and paired serum samples from 42 calves with respiratory disease were tested by ELISA for antibodies to the 3 viruses. Seroconversion to BVDV, BHV-1, and BRSV was found to 5, 2, and 6 farms out of the 8, respectively. The proportion of calves that showed seroconversion to BVDV, BHV-1, and BRSV were 19%, 14%, and 26%, respectively. In the second study, another farm having previous serological evidence of BVDV infection was selected. The decline of maternal antibodies against BVDV was monitored in 20 calves and the half-life of maternal antibodies was 34 +/- 12 days presumably indicating an early natural infection with BVDV. Furthermore, sera free of BVDV antibodies that were collected in studies 1 and 2 and were assayed for the presence of BVDV by nested RT-PCR. Two BVDV strains were detected and compared to those of ruminant and porcine pestiviruses. Both strains were assigned to subgroup Ib of type I BVDV. This investigation provides information on BVDV genotypes circulating in Venezuela and may contribute to the establishment of official control programmes against the viruses studied.     

Detection of viral antigen in placenta and fetus of cattle acutely infected with bovine viral diarrhea virus.

The reproductive organs and fetuses of seven Norwegian Red heifers were investigated for the presence of bovine viral diarrhea virus (BVDV) antigen during the time of initial transplacental transmission of the virus. The heifers were inoculated with a noncytopathogenic BVDV at day 85/86 of gestation and were slaughtered at day 7, 10, 14, 18, or 22 postinoculation (pi). Cryostat sections of uterus, ovaries, placentomes, intercotyledonary fetal membranes, and fetal organs were examined using immunohistochemical techniques. A double immunofluorescence technique was used to identify cells that showed staining with antibodies against the leukocyte common antigen CD45 or the intermediate filament vimentin and BVDV antigens. The earliest stage of infection at which BVDV antigen could be detected in the fetuses was 14 days pi. At this stage, BVDV antigen was detected in cells of mesenchymal origin in the lungs and in large cells that morphologically resembled immature megakaryocytes in the liver. In the intercotyledonary fetal membranes and in the placentomes, BVDV antigen was not detected until 18 and 22 days pi, respectively. BVDV antigen was not detected in maternal tissue from any of the heifers. The present results indicate that fetal infection with BVDV can take place without preceding or simultaneous high concentrations of BVDV in uterus or placenta of acutely infected heifers.     

Percutaneous collection of fetal fluids for detection of bovine viral diarrhea virus infection in cattle

OBJECTIVE: To develop a method for percutaneous collection of fetal fluid from cattle in the late stages of gestation and determine whether bovine viral diarrhea virus (BVDV) can be isolated from such fluids. DESIGN: Case series. ANIMALS: 169 pregnant beef cattle. PROCEDURE: Animals were restrained in a squeeze chute, and hair was clipped from a region of the right flank. Pregnancy was confirmed, and fetal fluids were identified by means of abdominal ultrasonography. Fetal fluid was collected with a spinal needle. Virus isolation was performed on fetal fluids, WBC lysates from 160 live calves, and tissues from 12 calves that died or were aborted. Blood samples collected from adult cattle were assayed with an immunoperoxidase monolayer assay. RESULTS: Fourteen animals aborted or delivered premature calves within 3 weeks after fetal fluid collection; however, it could not be determined whether this was a complication of the procedure or attributable to other factors. Results of BVDV isolation from fetal fluid samples were negative for 168 animals. However, a noncytopathic BVDV was isolated from fetal fluid obtained from a 2-year-old heifer; results of the immunoperoxidase assay of serum from this heifer were also positive, and a noncytopathic BVDV was isolated from tissue specimens from a stillborn calf produced by this heifer. CONCLUSIONS AND CLINICAL RELEVANCE: Results suggest that fetal fluids can be collected percutaneously from cattle in the late stages of gestation and that virus isolation performed on fetal fluids can be used to identify fetuses infected with BVDV in utero. However, safety of the procedure could not be evaluated.     

Effect of passive immunity on the development of a protective immune response against bovine viral diarrhea virus in calves

OBJECTIVE: To determine whether passively acquired antibodies prevent development of a protective immune response to live virus in calves. ANIMALS: 18 calves. PROCEDURES: Calves were caught immediately after birth and tested free of bovine viral diarrhea virus (BVDV) and serum antibodies against BVDV. Within 48 hours, 12 calves were fed colostrum that contained antibodies against BVDV and 6 calves received BVDV antibody free milk replacer. Three milk replacer fed and 6 colostrum fed calves were exposed to virulent BVDV2-1373 at 2 to 5 weeks of life when passively acquired serum antibody titers were high. After serum antibody titers against BVDV had decayed to undetectable concentrations (at 7 to 9 months of age), the 3 remaining milk replacer fed calves, 6 colostrum fed calves previously exposed to BVDV2-1373, and 6 colostrum fed calves that had not been exposed to the virus were inoculated with BVDV2-1373. RESULTS: Passively acquired antibodies prevented clinical disease in inoculated colostrum fed calves at 2 to 5 weeks of life. Serum antibody titers did not increase in these calves following virus inoculation, and serum antibody titers decayed at the same rate as in noninoculated colostrum fed calves. Inoculated colostrum fed calves were still protected from clinical disease after serum antibody titers had decayed to nondetectable concentrations. Same age colostrum fed calves that had not been previously exposed to the virus were not protected. CONCLUSIONS AND CLINICAL RELEVANCE: A protective immune response was mounted in calves with passive immunity, but was not reflected by serum antibodies titers. This finding has implications for evaluating vaccine efficacy and immune status.     

A short incubation serum neutralization test for bovine viral diarrhea virus.

A three day serum neutralization (SN) test for the detection of antibodies to bovine viral diarrhea virus (BVDV), which is an improvement on the existing five day test, is described. The improved test results in a more rapid viral cytopathic effect and utilizes Madin Darby kidney (MDBK) cells, and horse serum as a medium supplement. A comparison of tests utilizing the NADL and the Singer strains of BVDV and the use of either secondary bovine kidney cells with calf serum (BKCS) or continuous MDBK cells with horse serum (MDHS) was performed. Analysis of the SN results of 685 serum samples from 445 Quebec and Ontario cattle showed that there was no difference, as expected, in the means of the SN antibody titers when the NADL strain was used in either the BKCS or MDHS system but SN antibody titers were elevated (p less than 0.01) when the Singer strain was used in the MDHS system. The SN test with the Singer strain also yielded significantly higher titers for sera from 200 Alberta cattle.     

Enzyme-linked immunosorbent assay for the detection of antibodies to bovine viral diarrhea virus in bovine sera

A specific and sensitive enzyme-linked immunosorbent assay (ELISA) was established for the detection of antibodies to bovine viral diarrhea virus (BVDV) in bovine sera. Polyethylene-glycol concentrated, equilibrium density gradient purified BVDV was used as test antigen at an optimal amount of 1 microgram/well, whereas the optimal concentration of conjugate was at 1/2000 dilution. The standardized test encountered no non-specific reaction with test sera at a starting dilution of 1/10. A total of 50 bovine serum samples was assayed for the presence of antibodies against BVDV by ELISA and serum neutralization test (SNT). A positive correlation between the 2 tests was found. However, ELISA could be as much as 500-fold more sensitive than SNT in detecting low levels of BVDV antibodies.     

Fetal protection against bovine viral diarrhea virus types 1 and 2 after the use of a modified-live virus vaccine

The objective of this study was to demonstrate the efficacy of a modified-live virus (MLV) vaccine in protecting fetuses from infection with type 1 or type 2 Bovine viral diarrhea virus (BVDV) when pregnant heifers were challenged at approximately 170 d of gestation with noncytopathic field isolates. The 83 pregnant heifers had been bred naturally 4 wk after vaccination. Fetuses were collected 60 d after BVDV type 2 challenge, and newborn calves were collected before colostrum intake after BVDV type 1 challenge. Protection was determined by measuring the serum neutralizing (SN) antibody response in the fetus or calf and by virus isolation from thymus, lung, spleen, and kidney tissue samples. There was a measurable SN antibody response to BVDV in all the fetuses and calves of the control heifers, which had received a placebo vaccine. However, only 4 of 22 calves and 7 of the 28 fetuses of the MLV-vaccinated heifers demonstrated SN antibody after BVDV challenge. Type 1 BVDV was isolated from tissue samples of 5 of the 12 calves of control heifers and none of 22 calves of the MLV-vaccinated heifers challenged with type 1 BVDV. Type 2 BVDV was isolated from tissue samples of 17 of the 18 fetuses of the control heifers and 2 of the 28 fetuses of the MLV-vaccinated heifers challenged with type 2 BVDV. The results of this study demonstrate that the MLV vaccine reduces the fetal infection rate by at least 82% for BVDV type 1 and by 75% for BVDV type 2 when heifers are exposed to highly fetotrophic BVDV at 170 d of gestation.     

Quantification,risk factors,and health impact of natural congenital infection with bovine viral diarrhea virus in dairy calves

OBJECTIVES: To estimate risk and identify risk factors for congenital infection with bovine viral diarrhea virus (BVDV) not resulting in persistent infection and examine effect of congenital infection on health of dairy calves. ANIMALS: 466 calves. PROCEDURES: Calves from 2 intensively managed drylot dairies with different vaccination programs and endemic BVDV infection were sampled before ingesting colostrum and tested with their dams for BVDV and BVDV serum-neutralizing antibodies. Records of treatments and death up to 10 months of age were obtained from calf ranch or dairy personnel. Risk factors for congenital infection, including dam parity and BVDV titer, were examined by use of logistic regression analysis. Effect of congenital infection on morbidity and mortality rates was examined by use of survival analysis methods. RESULTS: Fetal infection was identified in 10.1% of calves, of which 0.5% had persistent infection and 9.6% had congenital infection. Although dependent on herd, congenital infection was associated with high BVDV type 2 titers in dams at calving and with multiparous dams. Calves with congenital infection had 2-fold higher risk of a severe illness, compared with calves without congenital infection. CONCLUSIONS AND CLINICAL RELEVANCE: The unexpectedly high proportion of apparently healthy calves found to be congenitally infected provided an estimate of the amount of fetal infection via exposure of dams and thus virus transmission in the herds. Findings indicate that congenital infection with BVDV may have a negative impact on calf health, with subsequent impact on herd health.     

Evolution of bovine viral diarrhea virus vaccines.

Control of bovine viral diarrhea virus (BVDV) infection is economically important to the cattle industry because the virus causes a variety of clinical diseases that adversely affect essentially all stages of the production cycle. Production losses primarily stem from reproductive failure and from immunosuppression during acute BVDV infection, which predisposes calves to respiratory or enteric diseases. Control is achieved by implementing herd health pro-grams focused on limiting exposure by avoiding persistently infected (PI) carrier cattle and by optimizing protective immunity through immunization. Vaccination cannot be relied upon solely to protect against fetal infection and losses due to BVD. This is because no single BVDV vaccine has been shown to give complete fetal protection. In addition to strategic use of vaccines, herd management practices should also be implemented to identify and eliminate PI carrier cattle and to avoid exposure to BVDV infection.     

Diagnosis of bovine viral diarrhea virus infection using monoclonal antibodies

The monoclonal antibody (MAb) D89 against bovine viral diarrhea virus (BVDV) was used in conjunction with fluorescein-conjugated anti-mouse immunoglobulin in an indirect fluorescent antibody (IFA) procedure on frozen tissue sections and cell culture. During the 2-year study, BVDV was isolated from specimens submitted in 460 cases. The D89 Mab detected all but 2 BVDV isolates, both cytopathic. In 316 of the cases in which BVD virus was detected by IFA, specimens were inoculated on bovine turbinate cells and examined for BVDV antigens at 3-5, 10, and 20 days postinoculation. The BVDV was detected in 238/316 cases (75%) after 3-5 days incubation. The remainder were not detected until 10 or 20 days postinoculation. Virus isolation was enhanced in the early test if plates were centrifuged at the time of inoculation. Results suggest that D89 monoclonal antibody is a suitable diagnostic reagent for the detection of BVDV isolated from diagnostic specimens. The D89 MAb can be used for the detection of BVDV in both cell culture and tissues. Combination of D89 with another BVDV MAb (C17) did not improve the ability to detect BVDV in tissues compared to using D89 only, and the combined Mab's resulted in an increase in nonspecific fluorescence when used on tissues. Although pooling of different BVDV monoclonal antibodies may be necessary to detect all strains of BVDV in cell culture, pooling should be used with caution on tissues. Early detection of BVDV in cell culture by this IFA procedure permits faster confirmation of BVDV diagnosis when compared to the usual routine testing for noncytopathic BVDV at termination of first passage in cell culture.     

Anti-idiotypic antibodies mimic bovine viral diarrhea virus antigen.

Polyclonal rabbit anti-idiotypic antibodies (anti-ids) against two neutralizing murine monoclonal antibodies (mAbs) specific to a bovine viral diarrhea virus (BVDV) glycoprotein, 53 kDa, were produced, purified, and characterized. Each anti-id inhibited the binding of its respective mAb to BVDV antigen in a competitive ELISA and blocked the immunoprecipitation of the 53 kDa protein by the mAb. The anti-ids also inhibited the virus-neutralizing activity of their homologous mAbs. These results suggest that the anti-ids bear an internal image of a BVDV antigen and mimic neutralizing epitopes on the 53 kDa protein. Treatment of MDBK cells with the anti-ids inhibited BVDV infection, indicating that they block a cellular component, such as a virus receptor, required for virus adsorption or entry. Inhibition of the homologous mAb and lack of inhibition of the heterologous mAb indicate that the anti-ids are specific for the unique antigen-binding sites on the mAbs.     

Fetal protection against continual exposure to bovine viral diarrhea virus following administration of a vaccine containing an inactivated bovine viral diarrhea virus fraction to cattle

OBJECTIVE: To evaluate the efficacy of a commercially available killed bovine viral diarrhea virus (BVDV) vaccine to protect against fetal infection in pregnant cattle continually exposed to cattle persistently infected with the BVDV. ANIMALS: 60 crossbred beef heifers and 4 cows persistently infected with BVDV. PROCEDURES: Beef heifers were allocated to 2 groups. One group was vaccinated twice (21-day interval between the initial and booster vaccinations) with a commercially available vaccine against BVDV, and the other group served as nonvaccinated control cattle. Estrus was induced, and the heifers were bred. Pregnancy was confirmed by transrectal palpation. Four cows persistently infected with BVDV were housed with 30 pregnant heifers (15 each from the vaccinated and nonvaccinated groups) from day 52 to 150 of gestation. Fetuses were then harvested by cesarean section and tested for evidence of BVDV infection. RESULTS: 1 control heifer aborted after introduction of the persistently infected cows. Bovine viral diarrhea virus was isolated from 14 of 14 fetuses obtained via cesarean section from control heifers but from only 4 of 15 fetuses obtained via cesarean section from vaccinated heifers; these proportions differed significantly. CONCLUSIONS AND CLINICAL RELEVANCE: A commercially available multivalent vaccine containing an inactivated BVDV fraction significantly reduced the risk of fetal infection with BVDV in heifers continually exposed to cattle persistently infected with BVDV. However, not all vaccinated cattle were protected, which emphasizes the need for biosecurity measures and elimination of cattle persistently infected with BVDV in addition to vaccination within a herd.     

Development and evaluation of a MAb based competitive-ELISA using helicase domain of NS3 protein for sero-diagnosis of bovine viral diarrhea in cattle and buffaloes

The aim of this study was to develop a competitive inhibition ELISA (CI-ELISA) for detection of antibodies to bovine viral diarrhea virus (BVDV) using the helicase domain of NS3 (non-structural) protein and monoclonal antibody (MAb) against it and to estimate its sensitivity and specificity using two commercial ELISA kits as independent references. The 45-kDa helicase domain of NS3 protein of BVDV was expressed in Escherichia coli and 18MAbs were developed against it. MAb-11G8 was selected for use in CI-ELISA on the basis of maximum inhibition (90%) obtained with BVDV type 1 infected calf serum. Based on the distribution of percent inhibition of known negative sera (n=166), a cut-off value was set at 40% inhibition. In testing 914 field serum samples of cattle (810) and buffaloes (104), the CI-ELISA showed a relative specificity of 95.75% and 97.38% and sensitivity of 96% and 94.43% with Ingenesa kit and Institut Pourquier kit, respectively. This study proved that the use of helicase domain of NS3 (45-kDa) is equally good as the whole NS3 protein (80-kDa) used in commercial kits for detection of BVDV antibodies in cattle and buffaloes.     

Prevalence of bovine viral diarrhea virus infection in bulls in artificial insemination centers in Poland

This study was directed at the evaluation of the prevalence of bovine viral diarrhea virus (BVDV) infection in bulls in artificial insemination centers. Both serological and virological examinations were performed. Blood samples were tested in micro-seroneutralization test for BVDV antibodies. Virus isolation was performed in cell culture and BVDV antigen was detected in an indirect immunofluorescence assay with monoclonal antibodies. One hundred and seventy-five serum samples and 219 whole blood samples for virus isolation were tested. Neutralizing antibodies were found in 86% of the bulls. Persistent infection (PI) was detected in 0.9% of the analyzed blood samples.     

Viral contamination of bovine fetal lung cultures and bovine fetal serum

Commercial bovine fetal serum (BFS) and bovine fetal lung (BFL) cells were tested for viruses. The only virus detected in any samples was noncytopathogenic bovine viral diarrhea virus (BVDV). Of 37 BFL cultures initiated, 34 were negative for BVDV, 1 was positive, and 2 were suspicious in that the source of BVDV contamination was not certain. Of 9 lots of irradiated sera tested, 1 (10%) was positive for BVDV; of 21 lots of nonirradiated sera tested, 13 (62%) were positive for BVDV. As judged by intensity of fluorescence in infected cultures, some cell strains were much more susceptible to BVDV than other strains. Heat inactivation of serum at 56 C for 30 minutes was found to be an unreliable method of eliminating BVDV from sera.     

Predicted ages of dairy calves when colostrum-derived bovine viral diarrhea virus antibodies would no longer offer protection against disease or interfere with vaccination

OBJECTIVE: To develop models that could be used to predict, for dairy calves, the age at which colostrum-derived bovine viral diarrhea virus (BVDV) antibodies would no longer offer protection against infection or interfere with vaccination. DESIGN: Prospective observational field study. ANIMALS: 466 calves in 2 California dairy herds. PROCEDURE: Serum BVDV neutralizing antibody titers were measured from birth through 300 days of age. The age by which colostrum-derived BVDV antibodies had decayed sufficiently that calves were considered susceptible to BVDV infection (ie, titer < or = 1:16) or calves became seronegative was modeled with survival analysis methods. Mixed-effects regression analysis was used to model colostrum-derived BVDV antibody titer for any given age. RESULTS: Half the calves in both herds became seronegative for BVDV type I by 141 days of age and for BVDV type II by 114 days of age. Rate of antibody decay was significantly associated with antibody titer at 1 to 3 days of age and with whether calves were congenitally infected with BVDV. Three-month-old calves were predicted to have a mean BVDV type-I antibody titer of 1:32 and a mean BVDV type-II antibody titer of 1:16. CONCLUSIONS AND CLINICAL RELEVANCE: Results provide an improved understanding of the decay of BVDV-specific colostrum-derived antibodies in dairy calves raised under typical field conditions. Knowledge of the age when the calf herd becomes susceptible can be useful when designing vaccination programs aimed at minimizing negative effects of colostrum-derived antibodies on vaccine efficacy while maximizing overall calf herd immunity.